Palatin Technologies Inc PTN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if PTN is a good fit for your portfolio.
News
-
Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024
-
Palatin Announces Results of PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)
-
Palatin Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
-
Palatin to Report Second Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on February 15, 2024
-
Palatin Announces Database Lock for PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)
-
Palatin Announces Closing of $10 Million Registered Direct Offering
-
Thinking about buying stock in Arcus Biosciences, Palatin Technologies, Exxon Mobil, Archer Aviation, or Sidus Space ?
-
Palatin Announces $10 Million Registered Direct Offering
Trading Information
- Previous Close Price
- $1.82
- Day Range
- $1.81–1.91
- 52-Week Range
- $1.43–4.65
- Bid/Ask
- $1.81 / $1.91
- Market Cap
- $30.18 Mil
- Volume/Avg
- 239,619 / 730,930
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 3.62
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Palatin Technologies Inc is a part of the healthcare sector. The company is engaged in developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with unmet medical needs and commercial potential. Its programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its main product in clinical development is bremelanotide, which treats hypoactive sexual desire disorder, which is a type of female sexual dysfunction.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 33
- Website
- https://www.palatin.com
Valuation
|
Metric
|
PTN
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 3.62 |
Price/Cash Flow | — |
Price/Earnings
PTN
Financial Strength
|
Metric
|
PTN
|
|---|---|
Quick Ratio | 1.06 |
Current Ratio | 1.09 |
Interest Coverage | −1,774.45 |
Quick Ratio
PTN
Profitability
|
Metric
|
PTN
|
|---|---|
Return on Assets (Normalized) | −185.09% |
Return on Equity (Normalized) | −1,887.77% |
Return on Invested Capital (Normalized) | −1,295.90% |
Return on Assets
PTN
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Ndbgztghrt | Kxpc | $559.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Qdzdwlxw | Hfhtwc | $102.5 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Rjxprmkyz | Ybmzbfz | $98.6 Bil | |
MRNA
| Moderna Inc | Jwgjjrf | Jdzh | $41.0 Bil | |
ARGX
| argenx SE ADR | Pxlgvjm | Ngxdn | $22.6 Bil | |
BNTX
| BioNTech SE ADR | Yrvgxcnsv | Kqch | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Rxxkqwd | Yjjgwms | $18.8 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Hplkpsgr | Hbjnnh | $17.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Xcvzzshl | Hwqrkxw | $12.6 Bil | |
INCY
| Incyte Corp | Qkvgjsgt | Tsrxsd | $12.0 Bil |